[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642999":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":29,"locations":10,"responsibleParty":35,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":10},{"fullName":5,"class":6},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient",null,"Women with Fibromyalgia",[13,14],"Other: Quantitative Sensory Tests(QST) protocol","Other: Clinical Scales",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"Quantitative Sensory Tests(QST) protocol","including PPT Measurement with an Algometer, CPM and the Slow-Repeated Stimulated Pain Assessment Protocol",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Clinical Scales","Central Sensitization Inventory, Revised Fibromyalgia Impact Questionnaire, S-LANSS, Tampa Kinesiophobia Scale, Hospital Anxiety and Depression Scale, SF-12 Quality of Life Scale and Fatigue Severity Scale",[9],[25],{"name":26,"affiliation":27,"role":28},"Feyza Nur Yücel, Assoc. Prof.","Saglik Bilimleri Universitesi","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","(0216) 542 20 00","+90","dr.fny28@gmail.com",{"type":28,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Feyza Nur Yucel","Associate Professor","100642999",false,"NCT07640607","Investigation of Pain Modulation Phenotypes in Female Patients With Fibromyalgia","Inclusion Criteria:\n\n1. Having received a diagnosis of fibromyalgia according to the 2016 ACR diagnostic criteria\n2. Female patients aged 18-65\n3. Being literate\n4. Having signed the informed consent form upon agreeing to participate in the study\n\nExclusion Criteria:\n\n1. Being under 18 or over 65 years of age\n2. Having any condition that may lower the pain threshold or cause chronic pain (Rheumatoid Arthritis, Ankylosing Spondylitis, systemic inflammatory diseases, malignancies, etc.)\n3. Any neurological condition (stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies…)\n4. Peripheral artery disease\n5. Severe cardiopulmonary insufficiency (stage 3-4)\n6. Uncontrolled systemic diseases such as hypertension and diabetes\n7. Presence of an active infection\n8. Pregnancy\n9. Presence of cognitive impairment, hearing loss, or communication difficulties that would prevent understanding of questionnaires and protocols","FEMALE","18 Years","65 Years",{"count":47,"type":48},82,"ESTIMATED","OBSERVATIONAL","Fibromyalgia is characterized by altered pain processing, including impaired descending pain inhibition and central sensitization. While both mechanisms have been independently associated with disease severity, their interrelationship remains unclear. This cross-sectional study aims to investigate whether central sensitization symptoms mediate the relationship between conditioned pain modulation and fibromyalgia impact.",[52,53,54,55,56],"Fibromyalgia (FM)","Quantitative Sensory Testing","Central Sensitization","PRESSURE PAIN THRESHOLD","Pain Perception",[58,59,60],"Fibromyalgia","Pain sensitization","Conditioned pain modulation","NOT_YET_RECRUITING","2026-06-05",{"date":64,"type":65},"2026-06-11","ACTUAL",{"date":67,"type":48},"2026-06-01",{"date":69,"type":48},"2026-09-01",{"name":5,"class":6}]